Shares of Eli Lilly reached record highs on Monday, June 8, 2026, following the release of new clinical data for its next-generation obesity drug, retatrutide. The data, presented over the weekend at the American Diabetes Association's Scientific Sessions in New Orleans, reinforced investor confidence in the company's ...